First Bedside DNA Test to Be Introduced in the Baltics

Spartan Bioscience announces UAB DIAGNOSTINES SISTEMOS as exclusive distributor for Estonia, Latvia, Lithuania, and Belarus

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Spartan RX: Point-of-care DNA testing

There is an excellent opportunity for Spartan’s point-of-care DNA test in the Baltics.

-Dr. Julius Ptashekas, General Manager

Ottawa, Ontario (PRWEB) October 04, 2012

Spartan Bioscience today announced an exclusive distribution agreement with UAB DIAGNOSTINES SISTEMOS for distribution of the first bedside DNA test in Estonia, Latvia, Lithuania, and Belarus. UAB DIAGNOSTINES SISTEMOS specializes in the distribution of point-of-care medical diagnostic products, and will concentrate its efforts on reaching cardiologists in hospitals and other medical centers.

The Spartan RX CYP2C19 is the first bedside DNA test in medicine.(1) It identifies carriers of the CYP2C19*2 gene, which is carried by approximately 30% of the world’s population.(2) Genetic carriers who receive Plavix® (clopidogrel) following a cardiac stent have a 42 percent higher risk of death, stroke, or heart attack in the first year compared to non-carriers.(3) In 2009, Plavix® was the second best-selling drug in the world, with over $9 billion in revenues.

“We are excited to work together with UAB DIAGNOSTINES SISTEMOS,” said Paul Lem, M.D., CEO of Spartan Bioscience. “UAB DIAGNOSTINES SISTEMOS is experienced in bringing point-of-care medical tests to the Baltic market.”

“There is an excellent opportunity for Spartan’s point-of-care DNA test in the Baltics,” said Dr. Julius Ptashekas, General Manager of UAB DIAGNOSTINES SISTEMOS. “Cardiologists love new technologies that can improve patient care and lower costs.”

About the Spartan RX CYP2C19
The Spartan RX CYP2C19 is the first bedside DNA test in medicine.(1) It identifies carriers of the CYP2C19*2 gene in 1 hour. This gene is carried by approximately 30 percent of the world’s population.(2) Genetic carriers who receive Plavix® following a cardiac stent insertion to open clogged arteries have a 42 percent higher risk of death, stroke, or heart attack in the first year compared to non-carriers.(3) Currently, genetic testing is performed in central labs and it takes up to seven days to get a test result back. A rapid test is needed because most of the complications for CYP2C19 carriers occur in the first 24 to 48 hours.(3,4) In March 2010, the FDA issued a warning for Plavix regarding CYP2C19 poor metabolizers. The Spartan RX CYP2C19 has CE IVD Mark regulatory approval for Europe and other countries recognizing the CE IVD Mark. Spartan Bioscience is working towards FDA 510(k) clearance in the United States. For more information, please visit our website at: http://www.spartanbio.com/products/spartan-rx

About Spartan Bioscience
Spartan Bioscience is the leader in point-of-care DNA testing. The Spartan RX is the first complete sample-to-result, point-of-care DNA testing system in medicine. It is a fully integrated DNA collection, extraction and analysis platform, with an intuitive interface that is easy to operate—no laboratory training required. For the first time, healthcare providers and their patients can get DNA results on demand. For more information, please visit our website at: http://www.spartanbio.com.

The Spartan logo is a registered trademark of Spartan Bioscience Inc.
Plavix is a registered trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals.

1. Roberts JD et al. (2012). Lancet. 379: 1705–1711.
2. Damani SB, Topol EJ. (2010). J Am Coll Cardiol. 56:109–111.
3. Mega JL et al. (2009). N Engl J Med. 360:354–362.
4. Wiviott SD et al. (2007). N Engl J Med. 357:2001–2015.


Contact